Sentynl Therapeutics, Inc. Welcomes Michael Hercz as Its Senior Vice President and General Counsel
San Diego, CA, April 30, 2016 --(PR.com)-- Sentynl Therapeutics, Inc. (“Sentynl”) announced that Michael Hercz joined Sentynl as its Senior Vice President, General Counsel and Chief Compliance Officer.
Mr. Hercz brings more than 18 years of legal, compliance and risk management experience to Sentynl. Prior to Sentynl, Mr. Hercz served as a Director in Deloitte & Touche’s Enterprise Risk Services Group where he advised Fortune 500 Life Sciences management teams on leading industry practices. Previously, Mr. Hercz was Vice President and Chief Compliance Officer of Victory Pharmaceuticals where he oversaw the company’s corporate compliance program and served as a member of the executive team. Prior to joining Victory, Michael spent nearly eight years with Amgen Inc. in a series of increasingly senior legal, compliance and risk management roles. Prior to joining industry, Michael practiced law at the global law firm Akin, Gump, Strauss, Hauer & Feld LLP and at Hooper, Lundy & Bookman Inc. where he counseled Life Science industry clients on a broad range of issues, from complex transactions to white collar criminal investigations. Mr. Hercz earned his B.A. in Psychology from the University of Pennsylvania and his J.D. from the University of Southern California.
About Sentynl Therapeutics.
Sentynl provides healthcare professionals with treatment solutions that enable them to meet the needs of individual patients. Sentynl’s highly experienced and knowledgeable management team has previously built multiple successful pharmaceutical companies. With a focus on commercialization, Sentynl looks to source effective and well-differentiated products across a broad spectrum of therapeutic areas. Sentynl is committed to the highest ethical standards and compliance with all applicable laws, regulations, and industry guidelines.
For more information about Sentynl, please visit http://www.sentynl.com/.
Mr. Hercz brings more than 18 years of legal, compliance and risk management experience to Sentynl. Prior to Sentynl, Mr. Hercz served as a Director in Deloitte & Touche’s Enterprise Risk Services Group where he advised Fortune 500 Life Sciences management teams on leading industry practices. Previously, Mr. Hercz was Vice President and Chief Compliance Officer of Victory Pharmaceuticals where he oversaw the company’s corporate compliance program and served as a member of the executive team. Prior to joining Victory, Michael spent nearly eight years with Amgen Inc. in a series of increasingly senior legal, compliance and risk management roles. Prior to joining industry, Michael practiced law at the global law firm Akin, Gump, Strauss, Hauer & Feld LLP and at Hooper, Lundy & Bookman Inc. where he counseled Life Science industry clients on a broad range of issues, from complex transactions to white collar criminal investigations. Mr. Hercz earned his B.A. in Psychology from the University of Pennsylvania and his J.D. from the University of Southern California.
About Sentynl Therapeutics.
Sentynl provides healthcare professionals with treatment solutions that enable them to meet the needs of individual patients. Sentynl’s highly experienced and knowledgeable management team has previously built multiple successful pharmaceutical companies. With a focus on commercialization, Sentynl looks to source effective and well-differentiated products across a broad spectrum of therapeutic areas. Sentynl is committed to the highest ethical standards and compliance with all applicable laws, regulations, and industry guidelines.
For more information about Sentynl, please visit http://www.sentynl.com/.
Contact
Sentynl Therapeutics, Inc.
Whitney Nelsen
888-227-8725
www.sentynl.com/
Whitney Nelsen
888-227-8725
www.sentynl.com/
Contact
Categories